ReGelTec, Inc’s Post

Ophthopedia Update:The Rate of Retreatment in Patients treated with teprotumumab: A Multicenter Study of 119 Patients with 1 year Follow Up: To determine the rate of retreatment in patients who receive a full course of teprotumumab therapy for Thyroid Eye Disease (TED) and drivers of retreatment. #Ophthalmology #ophthotwitter #eyecare

For patients suffering from chronic limb-threatening ischemia (CLTI) below-the-knee (BTK), the cavalry is on the way…. #AbbottProud Esprit™ BTK Everolimus Eluting Resorbable Scaffold System is now FDA approved, offering a new treatment option for people battling chronic limb-threatening ischemia (CLTI) below-the-knee (BTK), the most severe form of peripheral artery disease (PAD). Discover how this first-of-its-kind dissolvable stent was designed to address unmet needs in the peripheral anatomy to help more people live better, fuller lives. Important Safety Info: https://lnkd.in/evH6F74u https://lnkd.in/g4eiJFZt

Fresh off the press: The first comparative trial showing benifit for rotational/hybrid atherectomy of popliteal artery occlusive disease in terms of freedom from re-intervention compared to a DCB only strategy (The EN-MOBILE-trial). Overall low bail-out stenting rates of 3% for the common femoral and 6% for the popliteal. GRN Klinik Weinheim GRN-Klinik Eberbach

💉 Calling all rheumatologists: consider using intravenous methylprednisolone (125 - 500 mg daily X 3 doses) at diagnosis time in #SLE #lupus to increase the chances for long-term remission in those with moderate to severe disease: https://lnkd.in/eSnyX6Re

Savara announced positive data from its Phase 3 IMPALA-2 trial of molgramostim, a nebulizer solution for treating autoimmune pulmonary alveolar proteinosis (aPAP). Read the full article here ⤵️ #LungDisease #QualityOfLife #AutoimmunePulmonaryAlveolarProteinosis

Are you utilizing the FIB-4 index in the management of metabolic dysfunction-associated steatotic liver disease (MASLD)? In this educational program, Dr. Naim Alkhouri explains the significance of the FIB-4 index in effective risk stratification for patients with MASLD. He shares expert insights on identifying at-risk patients, calculating the FIB-4 index, understanding the prognostic value of FIB-4, and implementing management strategies based on risk categories. Enhance patient care with this essential knowledge: https://ow.ly/Ygx450Snvqz #MedicalLearning #CME #LiverHealth #MASLD #PatientCare

Key opinion leaders (KOLs) interviewed by GlobalData highlight unmet needs in the kidney disease space, emphasizing the demand for next-generation therapies with alternate mechanisms of action. Ozempic, if approved, will be the first GLP-1 therapy option for patients with T2D and CKD. Learn more about how Ozempic can benefit CKD patients: #Healthcare #KidneyDisease #GlobalData #Ozempic #T2D #CKD

"Seladelpar improves markers of disease activity and reduces pruritus in patients with primary biliary cholangitis (PBC) who have an incomplete response or intolerance to ursodeoxycholic acid (UDCA), suggest findings from the phase 3 RESPONSE trial." Read the news article from our program 'Improving PBC outcomes by prioritising patient needs at https://lnkd.in/dx2wBivn --- This program is made possible thanks to an independent educational grant from Ipsen. #PBC #rarediseases #PBCawareness #PBCtherapy #independentmedicaleducation #ime #continuingmedicaleducation #cme #healthcareeducation #SpringerIME

Ok, so a bit more than just a weekly update, but what can I say? We've been busy! Here is what's going on at IAA lately: ●    Helped to redesign a #user interface to successfully mitigate use errors for a revalidation of a topical product to treat hyperhidrosis ●    Just finished an HF validation study on a REN device to treat migraines in children ●    Developing a commercial #IFU and formative study of a dry powder inhaler to treat pulmonary arterial hypertension (PAH) ●    Developing a clinical IFU and formative study of a dry powder inhaler to treat chronic lung conditions ●    Launching a nationwide comparative use study on an autoinjector for autoimmune disorders (Crohn’s Disease, ulcerative colitis, psoriatic arthritis, etc.) ●    Starting the HF validation of a reconstitution product to treat a rare disease that we have supported through development and clinical trials ●    Beginning the formative study of an innovative rescue device for anaphylaxis ●    Prepping for several comparative use studies with injection pens for weight loss and diabetes ●    Evaluating packaging and capsule blister designs for a new dry powder inhaler ●    Optimizing the user manual for a smart accessory for autoinjectors ●    Prepping for a HF validation study for an injection pen to treat multiple sclerosis

Poorly managed diabetes can lead to, Diabetic foot ulcer (DFU) and eventual amputation. It is compromising millions of lives across the globe. It happens due to the asynchronous interplay of molecular factors which leads to failure in wound resolution. In our recent publication we tried to share what went wrong in DFU and how it can be managed. An open access link for full text is available for this paper for 50 days Kindly read and share your feedback https://lnkd.in/ddY89Arn